Currently, the age of primiparous women is increasing, but the risk of cancer, which is sometimes found during gestation, is also increasing. This article discusses the problems of diagnosis and treatment of cancer during pregnancy, which occurs under the guise of gestational complications. Two cases of malignant neoplasms first discovered during pregnancy are described. The first observation illustrates cholangiocarcinoma in a 37-year-old multiparous, and the second is a case of colorectal cancer in a 40-year-old primiparous. The timely identification of such women is an important challenge of the outpatient, which in the future can help maintain the quality of life of the mother and child.
Aim. The article presents information on modern urethral bulking agents used in the treatment of female stress urinary incontinence (SUI).Materials and methods. The authors reviewed the current scientifi c literature on the topic (original articles, monographs, meta-analyses), whose relevance lies in the increasing interest of both clinicians and patients in the minimally invasive treatment of SUI.Results. On the basis of available information on the use of urethral bulking agents, regulatory bodies prohibited the use of substances that did not meet the requirements of safety and effi cacy. Substances approved for clinical use are safe and show considerable effect, which makes them a suitable alternative to the surgical treatment of SUI.Conclusions. This kind of treatment is characterised by a low rate of serious complications and a suffi ciently high level of patients’ satisfaction with the results, despite its lower objective cure rate. Further research in this area involves a search for the “ideal” urethral bulking agent, as well as the use of cell technologies.
The authors believe, that patients with purulent-inflammatory diseases of the uterus and its appendages, complicated widespread peritonitis, for values of blood procalcitonin level to 1.13 ng/mL can talk about abdominal sepsis without organ failure, at the level of 1.13-4.5 ng/mL should include developing organ failure 1-2 systems, that is, in this category of patients with high probability there is heavy abdominal sepsis with multiple organ failure laboratory level - disorders of the functioning of core indicators while maintaining homeostasis. If the levels of procalcitonin exceed 4.5 ng/ml, this indicates heavy abdominal sepsis with multiple organ failure in the progression multiple organ failure in multiple organ inconsistency. Reduction of procalcitonin in the postoperative period reflects a decrease in the body's inflammatory response, and reliable increase in the level of procalcitonin (and/or the absence of reduction) from the third day indicates the progression of the disease, which allows us to offer a method in monitoring and evaluating the effectiveness of the therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.